A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study

International Journal of Cancer

Volumn 128, Issue 10, 2011, Pages 2415-2424

  Levi, Zohar ^a   Birkenfeld, Shlomo ^a   Vilkin, Alex ^a   Bar Chana, Micha ^b   Lifshitz, Irena ^b   Chared, Miri ^a   Maoz, Eran ^a   Niv, Yaron ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b MINISTRY OF HEALTH   (Israel)

Author keywords

colorectal cancer; fecal occult blood test; FIT; G FOBT; guaiac; immunochemical test; screening; sensitivity; specificity

Indexed keywords

GUAIAC;

ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER REGISTRY; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DYSPLASIA; FEASIBILITY STUDY; FEMALE; GUAIAC FECAL OCCULT BLOOD TEST; HISTOPATHOLOGY; HUMAN; IMMUNOCHEMICAL FECAL OCCULT BLOOD TEST; IMMUNOCHEMISTRY; INTERMETHOD COMPARISON; ISRAEL; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; OCCULT BLOOD TEST; PATIENT PARTICIPATION; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SOCIAL STATUS; TUMOR VOLUME; URBAN POPULATION;

AGED; COLORECTAL NEOPLASMS; FEASIBILITY STUDIES; GUAIAC; HUMANS; MIDDLE AGED; OCCULT BLOOD; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; REGISTRIES; SENSITIVITY AND SPECIFICITY; SOCIAL CLASS;

EID: 79953169888     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25574     Document Type: Article

References (34)

1. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM,. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-7. (Pubitemid 26400242)
2. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O,. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-71. (Pubitemid 26400241)
3. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F,. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365-71. (Pubitemid 23131388)
4. Niv Y, Lev-El M, Fraser G, Abuksis G, Tamir A,. Protective effect of faecal occult blood test screening for colorectal cancer: worse prognosis for screening refusers. Gut 2002; 50: 33-7. (Pubitemid 34028300)
5. Niv Y,. Fecal occult blood test-the importance of proper processing. J Clin Gastroenterol 1990; 12: 393-5. (Pubitemid 20234366)
6. Young GP, Rozen P, Levin B,. How should we screen for early colorectal neoplasia. In:, Rozen P, Young GP, Levin B, Spann SJ, eds. Colorectal cancer in clinical practice. London: Martin Dunitz, 2002. 77-99.
7. Selinger RR, Nolman S, Dominitz JA,. Failure of health care professionals to interpret fecal occult blood tests accurately. Am J Med 2003; 114: 64-7. (Pubitemid 36126519)
8. Smith RA, Cokkinides V, Eyre HJ,. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003; 53: 27-43. (Pubitemid 36163620)
9. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on colorectal cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570-95. (Pubitemid 351615355)
10. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM,; American College of Gastroenterology. American College of Gastroenterology guidelines for colorectal cancer screening 2009. Am J Gastroenterol 2009; 104: 739-50.
11. Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, Niv Y,. Performance characteristics and evaluation of an automated developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005; 100: 2519-2.
12. Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y,. A quantitative immunochemical fecal occult blood test is more efficient for detecting significant colorectal neoplasia than is a sensitive guaiac test. Aliment Pharmacol Ther 2006; 23: 1359-64.
13. Levi Z, Rozen P, Hazazi R, Vilkin A, Maoz E, Birkenfeld S, Niv Y,. Can quantification of feacal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer? Aliment Pharmacol Ther 2006; 24: 1475-81. (Pubitemid 44657125)
14. Rozen P, Waked A, Vilkin A, Levi Z, Niv Y,. Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood. Med Sci Monit 2006; 12: MT27-MT32 (). (Pubitemid 43854430)
15. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Leshno M, Niv Y,. A quantitative immunochemical fecal occult blood screening test for colorectal neoplasia. Ann Intern Med 2007; 146: 244-55. (Pubitemid 351650610)
16. Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Niv Y,. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical fecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther 2009; 29: 450-7.
17. Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Leshno M, Niv Y,. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Aliment Pharmacol Ther 2009; 29: 906-17.
18. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E,. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90. (Pubitemid 351899018)
19. Wilson J, Junger Y,. Principles and practice of mass screening for disease. Public Health Paper No. 34. Geneva: WHO, 1968.
20. Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, Launoy G,. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer 2009; 100: 1230-5.
21. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y,. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129: 422-8. (Pubitemid 41096630)
22. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, Jansen JB, Verbeek AL, Dekker E,. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer 2009; 101: 1274-81.
23. Grazzini G, Visioli CB, Zorzi M, Ciatto S, Banovich F, Bonanomi AG, Bortoli A, Castiglione G, Cazzola L, Confortini M, Mantellini P, Rubeca T, et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009; 100: 259-65.
24. Grazzini G, Ciatto S, Cislaghi C, Castiglione G, Falcone M, Mantellini P, Zappa M,; Working Group of Regional Reference Centre for Oncological Screening of Tuscany. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence. J Med Screen 2008; 15: 175-81.
25. Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JCIY, van der Togt ACM, Habbema JDF, Kuipers EJ,. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59: 62-8.
26. Hughes K, Leggett B, Del Mar C, Croese J, Fairley S, Masson J, Aitken J, Clavarino A, Janda M, Stanton WR, Tong S, Newman B,. Guaiac versus immunochemical tests: faecal occult blood test screening for colorectal cancer in a rural community. Aust N Z J Public Health 2005; 29: 358-64. (Pubitemid 41670838)
27. Federici A,., Rossi PG, Borgia P, Bartolozzi F, Farchi S, Gasuticchi G,. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programes: a claster randomized controlled trial. J Med Screen 2005; 12: 83-8. (Pubitemid 40835139)
28. Ko CW, Dominitz JA, Nguyen TD,. Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am J Med 2003; 115: 111-4. (Pubitemid 37288838)
29. Hundt S, Haug H, Brenner H,. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150: 162-9.
30. Dancourt V, Lejeune C, Lepage C, Gailliard MC, Meny B, Faivre J,. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. Eur J Cancer 2008; 44: 2254-8.
31. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF,. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99: 1462-70.
32. Allison JE, Tekawa IS, Ransom LJ, Adrain AL,. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334: 155-9. (Pubitemid 26017953)
33. Castiglione G, Zappa M, Grazzini G, Mazzotta A, Biagini M, Salvadori P, Ciatto S,. Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. Br J Cancer 1996; 74: 141-4. (Pubitemid 26231992)
34. Robinson MH, Marks CG, Farrands PA, Thomas WM, Hardcastle JD,. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg 1994; 81: 448-51. (Pubitemid 24124835)